268 related articles for article (PubMed ID: 32015027)
1. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
[TBL] [Abstract][Full Text] [Related]
2. Yersinia pestis Exploits Early Activation of MyD88 for Growth in the Lungs during Pneumonic Plague.
Olson RM; Dhariwala MO; Mitchell WJ; Anderson DM
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30642901
[No Abstract] [Full Text] [Related]
3. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Sorgel F; Bassett J; Miller L; Sullivan LJ; Kinzig-Schippers M; Drusano GL
J Infect Dis; 2007 Sep; 196(5):782-7. PubMed ID: 17674322
[TBL] [Abstract][Full Text] [Related]
4. Modification of the Pulmonary MyD88 Inflammatory Response Underlies the Role of the Yersinia pestis Pigmentation Locus in Primary Pneumonic Plague.
Olson RM; Dhariwala MO; Mitchell WJ; Skyberg JA; Anderson DM
Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33257532
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
Russell P; Eley SM; Green M; Stagg AJ; Taylor RR; Nelson M; Beedham RJ; Bell DL; Rogers D; Whittington D; Titball RW
J Antimicrob Chemother; 1998 Feb; 41(2):301-5. PubMed ID: 9533478
[TBL] [Abstract][Full Text] [Related]
6. Standardized Method for Aerosol Challenge of Rodents with Yersinia pestis for Modeling Primary Pneumonic Plague.
Anderson PE; Olson RM; Willix JL; Anderson DM
Methods Mol Biol; 2019; 2010():29-39. PubMed ID: 31177429
[TBL] [Abstract][Full Text] [Related]
7. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
8. Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model.
Olson RM; Anderson DM
PLoS One; 2019; 14(5):e0217440. PubMed ID: 31121001
[TBL] [Abstract][Full Text] [Related]
9. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Sha J; Agar SL; Baze WB; Olano JP; Fadl AA; Erova TE; Wang S; Foltz SM; Suarez G; Motin VL; Chauhan S; Klimpel GR; Peterson JW; Chopra AK
Infect Immun; 2008 Apr; 76(4):1390-409. PubMed ID: 18227160
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor CXCR2 mediates bacterial clearance rather than neutrophil recruitment in a murine model of pneumonic plague.
Eisele NA; Lee-Lewis H; Besch-Williford C; Brown CR; Anderson DM
Am J Pathol; 2011 Mar; 178(3):1190-200. PubMed ID: 21356370
[TBL] [Abstract][Full Text] [Related]
11. Tn-Seq Analysis Identifies Genes Important for Yersinia pestis Adherence during Primary Pneumonic Plague.
Eichelberger KR; Sepúlveda VE; Ford J; Selitsky SR; Mieczkowski PA; Parker JS; Goldman WE
mSphere; 2020 Aug; 5(4):. PubMed ID: 32759339
[TBL] [Abstract][Full Text] [Related]
12. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Eddy JL; Schroeder JA; Zimbler DL; Caulfield AJ; Lathem WW
J Thromb Haemost; 2016 Sep; 14(9):1833-43. PubMed ID: 27377187
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92.
Agar SL; Sha J; Foltz SM; Erova TE; Walberg KG; Baze WB; Suarez G; Peterson JW; Chopra AK
Microbes Infect; 2009 Feb; 11(2):205-14. PubMed ID: 19073275
[TBL] [Abstract][Full Text] [Related]
15. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
[TBL] [Abstract][Full Text] [Related]
16. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
17. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice.
Bubeck SS; Cantwell AM; Dube PH
Infect Immun; 2007 Feb; 75(2):697-705. PubMed ID: 17101642
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Inoculation of Mice with Yersinia pestis and Processing of Pulmonary Tissue for Analysis.
Pechous RD
Methods Mol Biol; 2019; 2010():17-28. PubMed ID: 31177428
[TBL] [Abstract][Full Text] [Related]
19. Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague.
Crane SD; Banerjee SK; Pechous RD
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0127521. PubMed ID: 34780267
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92.
Agar SL; Sha J; Foltz SM; Erova TE; Walberg KG; Parham TE; Baze WB; Suarez G; Peterson JW; Chopra AK
Microbiology (Reading); 2008 Jul; 154(Pt 7):1939-1948. PubMed ID: 18599822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
